CV Sciences (CVSI) Cash from Operations Growth (3y) (2014 - 2026)
CV Sciences (CVSI) Cash from Operations Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 8.25% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 52.97% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 5.90% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 43.42% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -10.08% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | -8.76% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 65.60% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | CV Sciences | 3.90 Mn | 3.63 Mn | 1.45 Mn | -75.80% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -75.80% |
| Mar 31, 2026 | -53.04% |
| Dec 31, 2025 | -50.79% |
| Sep 30, 2025 | 17.60% |
| Jun 30, 2025 | 30.95% |
| Mar 31, 2025 | 40.21% |
| Dec 31, 2024 | 47.96% |
| Sep 30, 2024 | 57.31% |
| Jun 30, 2024 | 73.50% |
| Mar 31, 2024 | 32.56% |
| Dec 31, 2023 | 57.34% |
| Sep 30, 2023 | 77.76% |
| Jun 30, 2023 | 37.24% |
| Mar 31, 2023 | 37.09% |
| Dec 31, 2022 | 26.94% |
| Sep 30, 2022 | 19.74% |
| Jun 30, 2022 | -34.51% |
| Mar 31, 2022 | -35.69% |
| Dec 31, 2021 | -34.66% |
| Sep 30, 2021 | -32.84% |